Allogene Therapeutics (ALLO) Osake Kurssi

Allogene Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Allogene Therapeutics Inc in the market include companies like Novartis AG, Pfizer Inc, and Cellectis SA.

Allogene Therapeutics Inc. is a biotechnology company specializing in the development of innovative cell therapies for cancer treatment. Founded in 2018, the company has quickly gained recognition for its groundbreaking approach to utilizing allogeneic, or off-the-shelf, CAR T cell therapy. With a mission to revolutionize cancer treatment, Allogene Therapeutics has established strategic partnerships and collaborations to accelerate the development and commercialization of their therapies. They aim to provide potentially curative treatments for patients battling various types of cancer. Allogene Therapeutics Inc. is committed to advancing the field of cellular immunotherapy in its quest to improve patient outcomes and transform cancer care.

Allogene Therapeutics Inc has achieved significant milestones since its establishment. Notably, the company successfully completed its initial public offering in October 2018, raising a substantial amount of capital to support its research and development efforts. The following year, Allogene Therapeutics initiated its first clinical trial evaluating its proprietary allogeneic CAR-T therapy, ALLO-501, for the treatment of relapsed/refractory non-Hodgkin lymphoma. Moreover, in 2020, the company received the prestigious Breakthrough Therapy Designation from the U.S. FDA for ALLO-501, recognizing its potential to address unmet medical needs. These achievements highlight Allogene Therapeutics' commitment to advancing innovative cellular therapies to transform the lives of patients with cancer.

Allogene Therapeutics Inc primarily operates in the United States.

Allogene Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize the field of cancer treatment by harnessing the potential of allogeneic cell therapies. By leveraging cutting-edge technologies and strategic partnerships, Allogene Therapeutics Inc strives to deliver transformative therapies to patients worldwide. With a focus on improving outcomes and addressing unmet medical needs, the company is committed to advancing breakthrough therapies for various types of cancer. Allogene Therapeutics Inc's dedication to scientific excellence and commitment to patients underscores its mission to bring novel cell therapies to market and improve the lives of those affected by cancer.

18 analyytikkoa arvioi tällä hetkellä Allogene Therapeutics-osaketta: 16 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Allogene Therapeutics-yhtiöltä 3,82 M USD liikevaihtoa ja −0,61 USD osakekohtaista tulosta.

Allogene Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Allogene Therapeutics-osake noteerataan hintaan 1,17 EUR (1,30 USD).

Allogene Therapeutics-osake (ALLO) on listattuna 1 pörssissä, muun muassa: NASDAQ (ALLO).

Allogene Therapeutics Inc is an innovative biopharmaceutical company specializing in the development of allogeneic CAR-T therapies for the treatment of severe cancers. The company focuses on developing gene therapies that can specifically target and destroy cancer cells due to their high effectiveness and specific mode of action. The company has a unique business model that enables the development and commercialization of cancer treatments in innovative ways. By using allogeneic cells from other donors instead of autologous cells from the patient, Allogene Therapeutics can offer faster and more cost-effective treatments. The treatment can be completed within a few weeks. The company aims to develop and market a wide range of allogeneic therapies for various types of cancer. They are working on developing gene therapies that selectively activate the immune system to fight cancer cells. One of their key drug candidates is ALLO-501, an allogeneic CAR-T cell therapy program used in combination with lymphodepletion in patients with non-Hodgkin lymphoma (NHL). The company also has a wide range of product candidates, including ALLO-715, used for the treatment of patients with severe multiple myeloma, and ALLO-647, an immunosuppressive molecule designed to prevent potential immune reactions against allogeneic cell therapies. Through a partnership with Servier, Allogene Therapeutics has also gained a strategic position in Europe. This partnership aims to expand access to allogeneic CAR-T cells to meet the needs of patients with difficult-to-treat blood cancers. Recently, the company completed a funding round of over $700 million to further advance its clinical studies and development pipeline. The company plans to use these funds to conduct additional clinical trials and bring their product candidates to market. As a leading provider of allogeneic CAR-T therapies, Allogene Therapeutics is committed to revolutionizing cancer treatment. Their innovative business model and groundbreaking gene therapies have the potential to improve the lives of cancer patients worldwide and successfully fight against cancer.

odotettu liikevaihto Allogene Therapeutics on 3,82 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Allogene Therapeutics on −135,15 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Allogene Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,12. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Allogene Therapeutics-osakkeen arvostusta.

Allogene Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 75,12. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Allogene Therapeutics-osakkeen arvostuskennuslukuna.

Allogene Therapeutics:n Eulpool-laatuscore on 2/10.

Allogene Therapeutics:n ISIN on US0197701065. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Allogene Therapeutics:n WKN on A2N6WN. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Allogene Therapeutics:n ticker on ALLO. Tämä pörssinoteeraus käytetään Allogene Therapeutics-osakkeiden kauppaan pörssissä.